Advertisement

Reactions Weekly

, Volume 1694, Issue 1, pp 156–156 | Cite as

Dasatinib

Membranous glomerulonephritis, focal segmental glomerulosclerosis and nephrotic syndrome: 8 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series from the Lareb and EudraVigilance database, eight patients (1 male and 7 females) within 11−70 years of age [specific ages not stated] were described, who developed membranous glomerulonephritis, focal segmental glomerulosclerosis or nephrotic syndrome during treatment with dasatinib [dosage and route not stated; not all indications, times to reactions onsets and outcomes stated].

Patient 1: A male in the age group 11−20 years was identified from the Lareb database. He had Philadelphia chromosome (Ph)-positive acute lymphoblastic leukaemia and started receiving treatment with dasatinib 60 mg/m2 once a day. Twenty-seven days1following the initiation of dasatinib, he developed nephrotic syndrome including oedema with a 6kg weight gain, proteinuria with a...

Reference

  1. Muller-Hansma AHG, et al. Nephrotic syndrome under treatment with dasatinib: Be aware of a possible adverse drug reaction. Netherlands Journal of Medicine 75: 428-431, No. 10, Dec 2017 - NetherlandsGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations